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ABSTRACT 
The document of ethical approval is an important official requirement for research involving human participants worldwide. It 
is the process whereby an investigator submits the full research proposal and related documents including detailed informed 
consent process to an independent Institutional Review Board (IRB) for scrutiny. The process of seeking review and approval is 
necessary to ensure adequate measure are in place to safeguard and protect research participants as entrenched in the principles 
of The Declaration of Helsinki and The Belmont Report. It is the responsibility of every clinical researcher to obtain ethical 
approval, therefore, their obligation to understand the process of review and establish relationship with local IRB in order to 
enhance smooth review and approval. This article, therefore, explains clinical research and distinguishes between research and 
clinical care, clarifies briefly what constitutes a study protocol and describes the researchers' relationship with IRB 
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The idea of writing a study proposal is often the starting point 
after conceptualizing the research idea and defining the gaps 
to be filled. This is probably one of the most difficult aspects 
of human research, in particular among graduates and young 
investigators in academics. Writing a research proposal 
involving human participants requires paying attention to the 
basics of ethical standards in accordance with The 
International Council on Harmonisation (ICH) Good Clinical 
Practice (GCP) guidelines (Bhuiyan and Rege, 2001). 
Worldwide, any research involving human subjects is 
expected to be subjected to review and approval of a properly 
constituted Institutional Review Board (IRB) which would 
examine the details of the protocol in order to safe guide the 
right and safety of future potential participants (ICH-GCP, 
1996). 
 The ICH-GCP is a “harmonized standard guideline that 
protects the rights, safety and wellbeing of human research 
participants, minimizes human exposure to investigational 
products, improves quality of data, speeds up marketing of 
new drugs and decreases the cost to sponsors and to the 
public” (ICH-GCP, 1996; Sherke and Rao, 2001; 
Vijayananthan and Nawawi, 2008). When research complies 
with this standard, the public is reassured that the rights, safety 
and well- being of persons who participated are protected, in 
accordance with the principles of the Helsinki Declaration, 
and that the data are considered valid [Bhuiyan and Rege, 
2001, WMA, 2004). 
 To be ethically acceptable,a clinical study must be reviewed 
and approved by the IRB. The IRB determines whether the 
risk to potential participants of the proposed study is 
minimized and reasonable in relation to the relevance of the 
expected knowledge and outcomes (WMA, 2004). However, 
the process of writing an acceptable study protocol related to 
the existing IRB and meeting the requirement for obtaining 
approval could be a challenging task for many students and 
young researchers. The purpose of this article, therefore, is to 
briefly explain what constitute a study protocol, describe the 
relationship of investigator with IRB and highlight the 
expectations of the IRB. 
 
CLINICAL RESEARCH VERSUS CLINICAL 
PRACTICE 
Clinical research or clinical trials are often confused with 
clinical practice (that is medical care). If the physician is also 
a researcher, this subject can be particularly confusing. When 
the physician provides the medical care, he or she develops a 
care plan just for the individual patients. But in clinical 
research, the lead researcher and his/her co-investigators must 
follow a set plan called the "study protocol" such that 
everyone including the patients are placed under obligation 
follow it (Barlow, 1981). 
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 According to the Department of Health and Human Services 
(DHHS) Definitions (45 CFR 46.102), clinical research is any 
"activity designed to test hypothesis, allow conclusions and 
thereby develop or contribute to generalizable knowledge 
(expressed in theories, principles and relationship 
statements)" (USDHHS, 2018). Clinical practice entails 
administration of intervention and related-activities designed 
solely to improve the well-being of individual patients or 
clients and has reasonable expectations of success, it is 
intended to provide the particular individuals with diagnosis, 
preventive treatment or therapy. The aim of clinical research 
is to develop useful knowledge about human health and 
disease and ways of preventing, diagnosing and treating 
disease. The goal is not to benefit participants (although there 
are sometimes benefits) but the society at large because a 
relatively larger number of people than research participants 
would obviously benefit from the outcome of the research. 
Some of the differences between clinical research and medical 
care, as described on the website of the U.S. Food and Drug 
Administration (2018) are listed in Table 1.  
 In clinical research, people are the means to develop the 
intended useful knowledge and these people are undoubtedly 
at risk of being exploited. Thus, one of the intentions of ethics 
is to safeguard and protect the research participants from the 
potential risk associated with research (WMA, 2001). 
Confidentiality is an vital part of clinical research which 
dictates that personal information can be viewed by only those 
authorized to access it. It also means that only individual 
patients and researchers are aware of the clinical trial 
participants’ personal identity and all medical information 
(Giordano et al, 2007). The results of a study are therefore 
usually only presented trends or results without mention of 
specific participants data. 
 People participate in clinical research for different reasons 
(Alexander , 2010; Hussain‐Gambles, 2004, Grady, 2005). 
Some people take part in research because of poor assurance 
of the available standard treatment options or some of the side 
effects cannot be tolerated. If standard treatment options 
failed, clinical trials provide another option for finding a new 
one. Some other people take part in trials because they want 
to help promote medical knowledge. Notwithstanding the 
reason for participation, the interest and safety of participants 
in research must always be protected. This is why there are 
existing government agencies, boards of institutional review, 
professional standards, informed consent and legal standards. 
ROLES OF THE INSTITUTIONAL REVIEW BOARD 
 
The Institutional Review Board (IRB) is a regulatory body 
constituted to protect the rights and well-being of individuals 
selected to participate in research exercises (CIOMS, 2002). 
The IRB must review all research involving human 
participants before it begins. In accordance with the regulatory 
authority and existing institutional policies, the IRB has the 
authority to approve, criticize and monitor all research 
activities within its competence and to require changes. A 
typical IRB should consist of at least five members with 
different expertise capable of providing comprehensive 
review of the research protocol and related documents, 
including the material transfer agreement. 
 The IRB also takes into account the proposed research's 
institutional, legal, scientific and social implications. Each 
IRB must have at least one member who is not an institution's 
employee or affiliate and one member who is not a scientist. 
The IRBs often work with several experts or consultants who 
play advisory roles and are asked to review the protocol on a 
regular basis, especially in their area of expertise. Research 
ethics committees (RECs) must be truly independent when 
drawing up a judgment on how best to protect the rights and 
well-being of participants in the trial. Their independence 
ensures that any potential conflict of interests is not a real 
conflict. RECs are therefore responsible for acting primarily 
in the interests of potential participants in research and the 
communities concerned. One of the principal duties of IRB is 
to ensure potential participants are given information about the 
trial which is complete and comprehensible. Without this 
information, potential participants cannot consent. In addition, 
there are limits to what a competent person can consent to and 
the REC is responsible for ensuring that the trial interventions 
are themselves lawful and reasonable.  
 
THE STUDY PROTOCOL FOR IRB CONSIDERATION 
 
The development of a clinical protocol is the beginning of 
every clinical investigation. The study protocol is a document 
that describes each stage of the study and answers relevant 
questions on topics such as: the problem of public health to be 
addressed, the questions to be answered, what objectives the 
study will achieve, how much power the study will have, and 
the impact of the findings on public health.
 
Table 1:  
Clinical Research Versus Clinical Practice 
  Clinical Research Clinical Practice 
What is the aim? Answers specific questions through research involving 
numerous research volunteers. 
Address the medical needs of individual 
patients. 
Who Benefit? Generally designed and intended to benefit future patients. Intended to benefit the individual index patient. 
How long? Depends on the research protocol. Requires real-time decisions. 
Consent needed? Requires written informed consent. May or may not require informed consent. 
Protections of 
subjects 
Protected by regulatory agencies including IRB, 
professional organisations, and informed consent. 
Guided by boards of medical practice, 
professional organisation, treatment protocols, 
and legal standards. 
Access to 
Information 
Considered confidential intellectual property.  Available to the general public through product 
labelling.  
Adapted from the website of the U.S. Food and Drug Administration (2018)9 
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The most important document is perhaps the trial protocol 
(and any changes required during the study). The concern of 
IRB is often focused on whether the investigators’ proposed 
study is scientifically sound and that the potential research 
participants would be adequately safeguarded and their right 
protected. A critical attention is also often paid to the potential 
risk the participants are likely to be exposed and the planned 
activities to mitigated them.  
 A well-setup IRB would look out for standard content of a 
protocol as stated in the ICH Good Clinical Practice 
guidelines, which includes the following topics: 
1. Title Page, which include general information about the 
investigators and institutions involved in the study. 
2. Background Information which gives the description of 
the problem to be solved and insight into rationale for the 
study. It also answers the questions on what is known and 
unknown about the problem intended to be addressed. 
This section of the protocol should also itemize the study 
hypotheses without ambiguity. It is the background 
section of the protocol that give indication of whether or 
not there is sufficient scientifically valid reason for the 
research. Otherwise the IRB reserves the right to decline 
approval.   
3. Study aim and Objectives. The aim should address the 
overall objective of the study, while Specific Objectives 
should outline the measurable outcomes variables. These 
should not differ significantly from that in the approved 
proposal. Each of the objectives should be specific, 
measurable achievable within the scope and proposed 
setting(s) of the study.  
4. Study Design. The choice of a suitable study design must 
be guided by the main research question intended to be 
answered. It encompasses type, duration, sampling and 
sample size determination. The IRB want the details of 
the justifications for the choice of the sampling method 
and the determination of the optimum number of required 
participants.  
5. Selection and Exclusion of Participants. Research ethics 
committees examine eligibility criteria for studies to 
ensure that research does not take advantage of the 
vulnerable or exclude subjects who can benefit from 
study participation without good reason. Whether the 
benefits of participating in a study outweigh the potential 
risks is also a primary consideration in determining 
eligibility criteria. Ethical considerations can lead to the 
exclusion of pregnant and lactating women from children, 
adolescents and women in clinical trials. The exclusion of 
such patients does not, on the other hand, provide 
information on the benefits and risks of a drug in such 
patients, but may use the drug if approved. It is therefore 
important to consider whether these exclusions are really 
necessary on a case-by-case basis. 
6. Treatment of Research Participants. Before giving 
approval, the IRB is responsible for ensuring that 
researchers clearly describe the details of treatments to be 
given to individuals participating in research. It is ethical 
only when all participants are offered the best standard 
treatments available. For this reason, the IRB frowns on 
the use of placebo, except when it can be absolutely 
proven that there is no other treatment option. 
7. Data Management and Statistical Analysis. The essence 
of this section in the proposal to be submitted to the IRB 
is to highlight the steps that will be taken by investigators 
and sponsors in order to protect the fundamental rights 
and fundamental freedom of the natural person in 
accordance with the public interest in relation to the 
processing of personal data. It must be taken into account 
that no personal or sensitive data is collected that is not 
essential to the research. If possible, the necessary data 
should be collected without using personally identifiable 
information. If personal information is required, it is 
necessary to de-identify the data when it is collected or as 
soon as possible. In addition to the issue of the protection 
of personal data, the data analysis methods must follow a 
sound scientific approach capable of producing valid 
results. Analysis and reporting of all data are a laudable 
ideal, but it is not always possible to report everything that 
has been done, researchers must decide which data points 
and analytical methods be presented. 
8. Ethical considerations. Most research ethics committee 
statutorily evaluate the extent of investigators compliance 
with the ethical principles as stated in the Declaration of 
Helsinki which details guideline governing the conduct of 
medical research (WMA, 2004). One of the main 
consideration is the detail of informed consent process. 
The Helsinki Declaration stipulated that “valid consent is 
properly informed and also freely given, without 
pressures such as coercion, threats or persuasion”. The 
informed consent procedure must provide details on: (a) 
the purpose of the research; (b) eligibility criteria and why 
the individual is suitable for the research; (c) risks and 
benefits to potential participants; (d) the right to 
voluntarily accept to participate or refused to do so; (e) 
the right to withdraw from the study at any time without 
losing any of the entitled privileges; (f) evidence of 
consenting in the presence of at least an independent third 
party who is not part of the research; (g) how each 
participant will be given sufficient time to review the 
consent document and ask questions prior to consenting 
to participate; and (h) translation of the content of the 
informed consent to native languages for full 
understanding of the participants. It is also important to 
note that the consent document must have provision for 
the signature of all parties and contacts of the lead 
investigator and chairman of the IRB.  
The Investigator and Institutional Review Board 
The person responsible for conducting clinical research at the 
study site is an investigator. If a group of scientists conducts a 
study, the principal investigator is the team leader responsible 
for all activities (Sade and  McKneally, 2002; Chilengi, 2009). 
On the other hand, the IRB is an official body experts 
constituted to protect the rights and well-being of research 
participants recruited to participate in research activities 
carried out under the supervision of an institution (Klitzman, 
2012). An IRB reviews the appropriateness of the protocol, the 
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risks and benefits for study participants. It ensures that 
participants in clinical research are exposed to minimal risks 
in relation to any benefits that might result from the research 
(Kim, 2012).  The responsibilities of investigators essentially 
focused on meeting the requirements for ethical review and 
approval in line with The International Council on 
Harmonisation (ICH) recommendations (ICH-GCP, 2001). 
Therefore, the lead investigators must demonstrate, in the 
protocol, that She/he:  
a. Is properly qualified to assume responsibility for the 
conduct of the study; 
b. Thoroughly familiar with the area of research interest and 
updated with the current knowledge; 
c. Willing to comply with ICH-GCP guideline and other 
applicable regulations and be prepared for monitoring and 
audits; and 
d. Responsible for ensuring adequate number of qualified staff 
and adequate facilities to complete the study. 
 
In addition, the investigator is responsible for continuing 
communication with IRB even after approval has been given. 
For example, the investigator is expected to report adverse 
events or other incidents during research as well as protocol 
amendments. It is mandatory to obtain new written approval 
from the IRB before any subsequent changes to the protocol 
are implemented. Investigators are responsible for ensuring 
that a witness is present during the consent process if a 
participant or their representative is incapable of reading and 
a copy of the signed consent form is provided to each 
participant.  
 
Difficulties of Investigators with Ethical Approval 
The preparation of an application for ethical approval is no 
different from the writing of a grant proposal. Most local IRB 
simply expect as much detail as would be written in a typical 
research protocol in the application for review and approval 
but with sufficient details on how the investigator(s) would 
ensure safety and protection of research participants as 
enshrine in the ICH-GCP guideline. Investigations often 
encounter difficulty in fulfilling the requirements of the IRB 
because of their failure to pay close attention to details 
(Lincoln YS, Tierney WG, 2004). This lack of attention to 
details is often the cause of delays in receiving reviewers’ 
comments and board’s approval. Aside, there are many 
instances in which clinical researchers’ view will conflict with 
their IRB’s. If the researcher is not fully aware of the IRB 
expectations and the application process, a conflict may arise. 
Since the ethical review process can vary from institution to 
institution, the investigator needs to be aware of the 
application process in advance. Avoidable delays can also be 
eliminated by providing answers to all questions on the 
application form and explaining how investigator conduct 
research ethically and comply with all regulations as explicitly 
as possible. 
 One of the likely problems in the course of seeking proposal 
approval is that the review can take longer time than usual 
thereby limiting clinical researchers in some ways. The 
relationship between the clinical investigator and their patients 
often depends on trust, which is not easily in line with 
predictable timetables and deadlines. Furthermore, the 
collection of data ought to be carried out within the time 
frames determined by other important events or the 
convenience of participants. In view of this, investigators need 
to always start the application process early, perhaps, many 
months before data collection begins. It should also be noted 
that IRBs are often restricted by guidelines which have firm 
conditions for the establishment of a minimum member of 
reviewers that must be at their meeting and prevent review by 
e-mail exchange or proxy. In order to avoid delay in IRB 
approval, investigators should always consider when the 
faculty and staff who serve as reviewers for IRB are likely to 
be busy. However, with the emerging online method of 
submission of proposal in institutions across the world, it is 
likely that there would significant reduction in review and 
approval turnaround time. No doubt, the online systems would 
help to remove some paperwork and shorten the review 
process. 
 All human research must receive approval from IRB before 
the commencement of recruitment of study participants and 
the collection of data. The process of submission therefore 
potentially adds to the amount of work to be done in research 
process. Thus, a third area of potential problem is lack 
experience of working with IRB and the difficulty of coping 
with adding the demand of research to the burden of giving 
lectures and providing clinical service.  
 In addition, there may also be potential friction because 
voluntary reviewers for IRB may be unaccustomed with the 
area of focus of the study proposal and the underlying 
intentions of research by practitioners. The task of review is 
therefore a daunting task for such reviewers. For this reason, 
it is critical that the researcher explicitly describe the purpose 
of their study and the rationale. Addressing these issues can be 
particularly tricky for young and inexperience investigators. 
The ethical principles of beneficence require that researchers 
adopt the most appropriate design to maximize gains and 
diminish potential harm to participants. 
 
Building Researcher Relationship With the IRB 
In view of some of the possible hitches that may arise between 
researchers and IRBs, it is appropriate for researchers to 
undertake a deliberate study and familiarize themselves with 
the regulation for the submission, review and approval of 
research proposals in their institution. Investigators should 
visit IRB Web site and/or their office to seek for information. 
Investigators need to spend time to read any document on IRB 
's application procedures and take note of planned training 
activities and instructions for submission. The investigators 
should determine whether their study meets the exempt or 
accelerated review criteria. The review of information 
published by IRB will help investigator to estimate the extent 
of the efforts required in preparing document for submission, 
including expected content of informed consent and 
procedures for handling individual participants’ data.  
 It is also often helpful to ask another faculty for advice. 
Faculty members who have passed the process can help the 
researcher better understand the regulatory ethos of the 
institution. Another way that an investigator can facilitate an 
IRB 's prompt review and approval is to carefully prepare 
applications and additional documents according to the 
instructions. The main points to remember is the completion 
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of all application forms correctly and accurately. Investigator 
does not need to mention risks that are not likely to happen to 
avoid raising needless cause for concern. There is no need to 
state risks to participants that are unlikely to occur, thereby 
raising unnecessary red flag. It is important to distinguish 
clearly between confidentiality and anonymity, which the 
investigator promises to uphold. The researcher should also 
clearly state ethical guidelines for the protection of the privacy 
of participants. 
 Each researcher is a potential member of the IRB in his 
institution. Therefore, volunteering to participate in an IRB 
panel is a good practice. The participation of faculty wide 
research committees and other academic review panel is a 
common way of acquiring academic review experience in 
their institution. Volunteering as an IRB reviewer, however, 
offers an opportunity to investigators to learn the process of 
review and common errors in application for ethical approval. 
Lastly, every research needs training on biomedical ethics and 
responsible conduct of research.  
 
Conclusion 
The approval of a research proposal by the IRB is essential in 
order to carry out a study that meets critical global standard. It 
improves the impression that the results of any research 
involving human participants are valid and reliable. Seeking 
ethical review and approval from IRB does not have to be 
frustrating if investigators would take the advantages of 
accessing information on the process and work closely with 
the office staff of their local IRB effectively. For example, the 
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